HRS-1596

Recent news mentioning HRS-1596

• 2026-09-29 — Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
• 2026-09-29 — Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596

Appears alongside

• Hengrui Pharma
• GLP-1/GIP

Browse the full archive →